biostudies-literatureJi YNCI NIH HHS4093-8https://www.ebi.ac.uk/biostudies/studies/S-EPMC4669593biostudies-literatureUnknown33(34)<h4>Purpose</h4>Progesterone receptors are expressed in approximately 70% of meningiomas. Mifepristone is an oral antiprogestational agent reported to have modest activity in a phase II study. This multicenter, prospective, randomized, placebo-controlled phase III trial conducted by SWOG was planned to define the role of mifepristone in the treatment of unresectable meningioma.<h4>Patients and methods</h4>Eligible patients were randomly assigned to receive either mifepristone or placebo for 2 years unless disease progressed. Patients who were stable or responding to protocol therapy after 2 years had the option to continue with the same blinded therapy. Serial follow-up allowed assessment of efficacy and toxicity. Time to treatment failure and overall survival were ascertained for all randJournal of clinical oncology : official journal of the American Society of Clinical OncologyDouble-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.PMC4669593U10 CA035176CA180835CA180834U10 CA035431N01 CA035119CA180830U10 CA073590U10 CA035192CA67663N01 CA045560U10 CA020319CA45461U10 CA046282U10 CA180830CA180819U10 CA180834U10 CA035119U10 CA067663CA180818U10 CA180835CA73590CA180858CA02115N01 CA035431U10 CA180858CA35192N01 CA035176CA180888CA58882N01 CA013612CA180846U10 CA180818U10 CA013612U10 CA180819CA180801CA180820CA46282U10 CA058882U10 CA180820U10 CA180801UG1 CA180830U10 CA180846U10 CA180888CA20319U10 CA045560U10 CA045461Grunberg SRussell CAVerschraegen CFredericks RKKabbinavar FFSchott AAhmadi JRankin CSherrod AETownsend JJFeun LGJi YStelzer KJfalseDouble-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.<h4>Purpose</h4>Progesterone receptors are expressed in approximately 70% of meningiomas. Mifepristone is an oral antiprogestational agent reported to have modest activity in a phase II study. This multicenter, prospective, randomized, placebo-controlled phase III trial conducted by SWOG was planned to define the role of mifepristone in the treatment of unresectable meningioma.<h4>Patients and methods</h4>Eligible patients were randomly assigned to receive either mifepristone or placebo for 2 years unless disease progressed. Patients who were stable or responding to protocol therapy after 2 years had the option to continue with the same blinded therapy. Serial follow-up allowed assessment of efficacy and toxicity. Time to treatment failure and overall survival were ascertained for all rand2015-01-01T00:00:00Z2015 Dec2026-05-10T00:41:42.823Z2020-10-29T10:35:49ZS-EPMC46695932652778110.1200/JCO.2015.61.649010.1200/jco.2015.61.6490